AbbVievs.Zoetis
ABBV vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 13× larger than Zoetis by market cap; Zoetis trades at the lower P/E (12.4 vs 120.6); year to date, AbbVie leads (+8.6% vs −39.9%).
Side by side
| ABBV | ZTS | |
|---|---|---|
| Market cap | $438B | $32.9B |
| Price | $248.08 | $75.56 |
| Today | −0.7% | +0.6% |
| Return YTD | +8.6% | −39.9% |
| Return 1Y | +27.2% | −52.4% |
| P/E | 120.6 | 12.4 |
| P/S | 7.0 | 3.5 |
| P/B | 308.7 | 10.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AbbVieABBV
Large biopharma with immunology (Skyrizi, Rinvoq), oncology and neuroscience.
Full ABBV profile →ZoetisZTS
The world’s largest animal health company — medicines and vaccines for pets and livestock, spun off from Pfizer in 2013.
Full ZTS profile →More comparisons in Big pharma
See where ABBV and ZTS sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →